

AMENDMENTS TO THE SPECIFICATION:

Please amend the paragraph on pages 8 and 9 lines 3-34, and 1 as follows:

Contemplated variants and hybrids are described in WO 96/23874, WO 97/41213, and WO 99/19467, and include the *Bacillus stearothermophilus* alpha-amylase (BSG alpha-amylase) variant, alpha-amylase TTC, having the following mutations delta(181-182) + N193F (also denoted I181* + G182* + N193F) compared to the wild-type amino acid sequence set forth in SEQ ID NO: ~~83 disclosed in WO 99/19467~~. Contemplated alpha-amylase derived from a strain of *Aspergillus* includes *Aspergillus oryzae* and *Aspergillus niger* alpha-amylases.

Please amend the paragraph on page 12 lines 23-28 as follows:

A preferred embodiment relates to the first aspect of the invention, wherein the glucoamylase is derived from *Talaromyces emersonii*, preferably from *Talaromyces emersonii* CBS 793.97; more preferably the glucoamylase has an amino acid sequence comprising one or more of the partial sequences shown in SEQ ID NOS: 1-6 of ~~WO 99/28448~~; even more preferably the glucoamylase has an amino acid sequence with an identity of at least 60% with SEQ ID NO: 7 of ~~WO 99/28448~~, or is a variant of the glucoamylase shown in SEQ ID NO: 7 of ~~WO 99/28448~~.

Please delete the previously submitted Sequence Listing and insert the attached Sequence Listing (pages 1-8) at the end of the specification.